Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31553772 | 0.95 | DDB1 (0.58) | DDB1CRBNPDK2TRIM24 | |
| SCHEMBL31553746 | 0.95 | DDB1 (0.58) | DDB1CRBNPDK2TRIM24 | |
| SCHEMBL31553813 | 0.95 | DDB1 (0.58) | DDB1CRBNPDK2TRIM24 | |
| SCHEMBL26837949 | 0.87 | CRBN (0.62) | DDB1CRBN | |
| SCHEMBL31003859 | 0.87 | CRBN (0.62) | DDB1CRBN | |
| SCHEMBL30289347 | 0.87 | DDB1 (0.64) | DDB1CRBN | |
| SCHEMBL31731322 | 0.86 | CRBN (0.66) | DDB1CRBN | |
| SCHEMBL21070729 | 0.86 | DDB1 (0.70) | DDB1CRBNTRIM24 | |
| SCHEMBL30392669 | 0.86 | DDB1 (0.65) | DDB1CRBN | |
| SCHEMBL26099555 | 0.86 | DDB1 (0.65) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025076044-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | DDB1 735/4885CRBN 13/4885PDK2 4341/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | DDB1 966/4885CRBN 49/4885PDK2 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.